Comparative Pharmacology
Head-to-head clinical analysis: MPI DMSA KIDNEY REAGENT versus SODIUM PHOSPHATE P 32.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MPI DMSA KIDNEY REAGENT versus SODIUM PHOSPHATE P 32.
MPI DMSA KIDNEY REAGENT vs SODIUM PHOSPHATE P 32
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DMSA (dimercaptosuccinic acid) labeled with technetium-99m binds to renal cortex, particularly proximal tubular cells, allowing scintigraphic imaging of functional renal parenchyma. Uptake correlates with renal blood flow and tubular function.
Sodium phosphate P 32 is a radioactive isotope that emits beta particles, causing ionization and subsequent cell death, particularly in rapidly dividing cells. It is incorporated into DNA and RNA, concentrating in tissues with high metabolic activity such as bone marrow and neoplastic cells.
Adults: 74-185 MBq (2-5 mCi) intravenously, single dose for renal imaging.
Intravenous administration: 1.5 mCi (55.5 MBq) per 70 kg body weight, single dose. For polycythemia vera, oral dose: 3-5 mCi (111-185 MBq) as a single dose. Frequency is one-time or as needed based on response.
None Documented
None Documented
Initial whole-body half-life of dimer captosuccinic acid (DMSA) is 1.1 hours; terminal elimination half-life for cortical retention is 56 days, reflecting prolonged renal tubular uptake.
Terminal elimination half-life: 14.3 days (range 13-16 days). Clinically relevant for bone marrow suppression monitoring; cumulative effect over multiple doses.
Renal: ~50% excreted unchanged in urine within 24 hours; remaining fraction retained in renal tubular cells with gradual release over weeks.
Renal: ~40% within 24 hours via glomerular filtration; Fecal: ~60% over 1-2 weeks as unabsorbed or secreted into bile. Total elimination approaches 100% after 2 weeks.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical